Turmeric – anti-nausea drug combo potent cancer killer

A new study has found that anti-nausea drug thalidomide when combined with common kitchen spice turmeric creates hybrid molecules that effectively kill multiple myeloma cells.

Thalidomide was first introduced in the 1950s as an anti-nausea medication to help control morning sickness, but was later taken off the shelves in 1962 because it was found to cause birth defects.

In the late 1990`s the drug was re-introduced as a stand-alone or combination treatment for multiple myeloma.

Turmeric, an ancient spice grown in India and other tropical regions of Asia, has a long history of use in herbal remedies and has recently been studied as a means to prevent and treat cancer, arthritis and Alzheimer`s disease.

According to the American Cancer Society, laboratory studies have shown that curcumin, an active ingredient in turmeric, interfere with several important molecular pathways and inhibit the formation of cancer-causing enzymes in rodents.

“Although thalidomide disturbs the microenvironment of tumor cells in bone marrow, it disintegrates in the body. Curcumin, also active against cancers, is limited by its poor water solubility. But the combination of thalidomide and curcumin in the hybrid molecules enhances both the cytotoxicity and solubility,” study`s lead researcher Shijun Zhang, assistant professor in the Department of Medicinal Chemistry at the VCU School of Pharmacy, said.

The study is published by the journal Organic and Biomolecular Chemistry.


New technology makes breast cancer surgery more precise

FDA approved MarginProbe in December 2012, and UC Irvine Medical Centre is the first hospital in the US to employ the system

Any breast cancer surgeon who regularly performs lumpectomies confronts the question “Did I get it all?” Thirty to 60 per cent of the time in the US, the answer is “no,” requiring the patient to undergo a second surgery to remove the remaining tumor.

Surgeons at UC Irvine Medical Centre are the first in the country to use a device that reduces by half the need to re operate and cut out breast cancer cells missed during an initial lumpectomy. The Margin Probe System lets the surgeon immediately assess whether cancer cells remain on the margins of excised tissue. Currently, patients have to wait days for a pathologist to determine this.

“All of my patients know someone who has had to go back into surgery because their doctor didn’t get the entire tumor out,” said UC Irvine Health surgical oncologist Dr Alice Police. “The ability to check tissue in the operating room is a game changer in surgery for early-stage breast cancer.”

The goal in a lumpectomy is to completely remove the cancer while preserving as much normal breast tissue as possible. If a pathologist finds cancer cells on the edges of the tissue taken out, surgeons must assume the lumpectomy didn’t get the entire tumor.

The Food and Drug Administration (FDA) approved MarginProbe in December 2012, and UC Irvine Medical Centre is the first hospital in the US to employ the system, according to manufacturer Dune Medical Devices.

Dr Police, assistant professor of surgery at UC Irvine and medical director of Pacific Breast Care in Costa Mesa, and Dr Karen Lane, associate professor of surgery and clinical director of the UC Irvine Health Breast Health Centre in Orange, began operating with MarginProbe in early March.

They had participated in an FDA trial that included more than 660 women across the US. In the prospective, multicentre, randomized, double-arm study, surgeons applied the device to breast tissue removed during in-progress initial lumpectomies and, if indicated, shaved additional tissue on the spot. This was found to reduce by 56 per cent the need for repeat surgeries.

“It will save you a lot of anxiety,” said Jane Madigan, a Costa Mesa resident who underwent the procedure with Dr Police as part of the MarginProbe trial. “You will come out of that surgery knowing you are cancer-free.”

The system comprises a sterile handheld probe and a portable console. When the probe tip touches an excised lumpectomy specimen, radio-frequency signals are transmitted into the tissue and reflected back to the console, where they are analyzed using a specialized algorithm to determine tissue status.

Source: http://www.indiamedicaltimes.com/2013/06/06/new-technology-makes-breast-cancer-surgery-more-precise/